BTIG Research Issues Positive Forecast for HealthEquity (NASDAQ:HQY) Stock Price

HealthEquity (NASDAQ:HQY) had its price target upped by equities researchers at BTIG Research from $110.00 to $130.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s target price would suggest a potential upside of 33.73% from the stock’s previous close.

Several other equities analysts have also recently weighed in on the company. Deutsche Bank Aktiengesellschaft raised their price objective on HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. JMP Securities reaffirmed a “market outperform” rating and set a $105.00 price target on shares of HealthEquity in a research report on Wednesday, September 4th. Royal Bank of Canada reissued an “outperform” rating and issued a $92.00 price objective on shares of HealthEquity in a report on Wednesday, September 4th. Bank of America boosted their target price on shares of HealthEquity from $100.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Barrington Research reiterated an “outperform” rating and issued a $105.00 price target on shares of HealthEquity in a research note on Friday, September 20th. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat.com, HealthEquity currently has an average rating of “Buy” and an average price target of $107.17.

HealthEquity Trading Up 2.5 %

HealthEquity stock traded up $2.41 during mid-day trading on Thursday, hitting $97.21. The stock had a trading volume of 229,381 shares, compared to its average volume of 614,078. The stock has a 50-day simple moving average of $84.24 and a two-hundred day simple moving average of $80.84. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $8.49 billion, a PE ratio of 80.70, a P/E/G ratio of 1.57 and a beta of 0.52. HealthEquity has a 12 month low of $62.10 and a 12 month high of $101.17.

HealthEquity (NASDAQ:HQY) last issued its quarterly earnings results on Tuesday, September 3rd. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.50 by $0.16. The company had revenue of $299.93 million during the quarter, compared to analysts’ expectations of $284.48 million. HealthEquity had a net margin of 9.61% and a return on equity of 9.01%. As a group, sell-side analysts forecast that HealthEquity will post 2.27 EPS for the current year.

Insider Activity

In other news, Director Frank Corvino sold 1,039 shares of the business’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $96.10, for a total value of $99,847.90. Following the completion of the sale, the director now owns 3,784 shares of the company’s stock, valued at approximately $363,642.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, Director Frank Corvino sold 1,039 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $96.10, for a total transaction of $99,847.90. Following the sale, the director now owns 3,784 shares of the company’s stock, valued at $363,642.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Robert W. Selander sold 8,250 shares of HealthEquity stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $82.98, for a total value of $684,585.00. Following the completion of the transaction, the director now directly owns 54,719 shares of the company’s stock, valued at $4,540,582.62. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,536 shares of company stock valued at $884,517. 2.20% of the stock is owned by insiders.

Hedge Funds Weigh In On HealthEquity

Several hedge funds have recently bought and sold shares of the company. Janney Montgomery Scott LLC boosted its stake in HealthEquity by 27.4% in the first quarter. Janney Montgomery Scott LLC now owns 3,970 shares of the company’s stock valued at $324,000 after buying an additional 855 shares in the last quarter. Swiss National Bank grew its holdings in shares of HealthEquity by 0.4% during the 1st quarter. Swiss National Bank now owns 169,300 shares of the company’s stock valued at $13,820,000 after purchasing an additional 600 shares during the last quarter. US Bancorp DE grew its holdings in shares of HealthEquity by 4.8% during the 1st quarter. US Bancorp DE now owns 11,489 shares of the company’s stock valued at $938,000 after purchasing an additional 521 shares during the last quarter. ProShare Advisors LLC lifted its stake in HealthEquity by 5.7% in the 1st quarter. ProShare Advisors LLC now owns 19,477 shares of the company’s stock valued at $1,590,000 after purchasing an additional 1,053 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System boosted its position in HealthEquity by 11.1% in the first quarter. State Board of Administration of Florida Retirement System now owns 26,663 shares of the company’s stock valued at $2,177,000 after buying an additional 2,660 shares in the last quarter. 99.55% of the stock is owned by institutional investors.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.